Equities

Biocytogen Pharmaceuticals Beijing Co Ltd

Biocytogen Pharmaceuticals Beijing Co Ltd

Actions
  • Price (EUR)0.705
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-51.04%
  • Beta--
Data delayed at least 15 minutes, as of Nov 12 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments408611566
Total Receivables, Net148112118
Total Inventory899583
Prepaid expenses122758
Other current assets, total657449
Total current assets723919874
Property, plant & equipment, net1,4511,5991,391
Goodwill, net------
Intangibles, net28316.06
Long term investments1881989.69
Note receivable - long term------
Other long term assets595322
Total assets2,4492,8002,303
LIABILITIES
Accounts payable175146102
Accrued expenses254059
Notes payable/short-term debt000
Current portion long-term debt/capital leases20317227
Other current liabilities, total174248259
Total current liabilities578606447
Total long term debt34124463
Total debt54441590
Deferred income tax1.90----
Minority interest4.554.554.76
Other liabilities, total739799541
Total liabilities1,6641,6541,056
SHAREHOLDERS EQUITY
Common stock399399375
Additional paid-in capital1,9921,9921,516
Retained earnings (accumulated deficit)(1580)(1228)(644)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total1.612.270.83
Total equity7861,1461,247
Total liabilities & shareholders' equity2,4492,8002,303
Total common shares outstanding399399397
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.